VerastemVSTM
VSTM logo
Fair Value
US$16.13
Share price22 Jan
US$6.5859.2% undervalued intrinsic discount
Loading
1Y-17.44%
7D-3.09%

RAS And MAPK Cancer Pipeline Will Drive Long Term Upside Potential

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
22 Jan 26
Views
68
Not Invested

Fair Value vs Share Price

US$16.13
vs US$6.5859.2% undervalued intrinsic discount
PastFuture-149m461m2015201820212024202620272029Revenue US$461.5mEarnings US$78.3m
225.5%
Revenue growth
17%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Verastem

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Undervalued with slight risk.

Market capUS$595.9m
PB11.9x
Estimated Growth37.8%
Dividend YieldN/A
Full analysis

CEO & management

Daniel Paterson
CEO
2.6yrs
CEO Tenure

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.